|
1
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhou YJ, Zheng W, Zeng QH, Ye Y, Wang C,
Fang C, Liu CJ, Niu L and Wu LM: Targeted exome sequencing
identifies mutational landscape in a cohort of 1500 Chinese
patients with non-small cell lung carcinoma (NSCLC). Hum Genomics.
15:212021. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Schiller JH, Harrington D, Belani CP,
Langer C, Sandler A, Krook J, Zhu J and Johnson DH; Eastern
Cooperative Oncology Group, : Comparison of four chemotherapy
regimens for advanced non-small-cell lung cancer. N Engl J Med.
346:92–98. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Camidge DR, Dziadziuszko R, Peters S, Mok
T, Noe J, Nowicka M, Gadgeel SM, Cheema P, Pavlakis N, de Marinis
F, et al: Updated efficacy and safety data and impact of the
EML4-ALK fusion variant on the efficacy of alectinib in untreated
ALK-positive advanced non-small cell lung cancer in the global
phase III ALEX study. J Thorac Oncol. 14:1233–1243. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ramalingam SS, Vansteenkiste J, Planchard
D, Cho BC, Gray JE, Ohe Y, Zhou C, Reungwetwattana T, Cheng Y,
Chewaskulyong B, et al: Overall survival with osimertinib in
untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 382:41–50.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang YL, Yuan JQ, Wang KF, Fu XH, Han XR,
Threapleton D, Yang ZY, Mao C and Tang JL: The prevalence of EGFR
mutation in patients with non-small cell lung cancer: A systematic
review and meta-analysis. Oncotarget. 7:78985–78993. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Grigoriu B, Berghmans T and Meert AP:
Management of EGFR mutated nonsmall cell lung carcinoma patients.
Eur Respir J. 45:1132–1141. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Harrison PT, Vyse S and Huang PH: Rare
epidermal growth factor receptor (EGFR) mutations in non-small cell
lung cancer. Semin Cancer Biol. 61:167–179. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jahanzeb M, Lin HM, Pan X, Yin Y, Wu Y,
Nordstrom B and Socinski MA: Real-world treatment patterns and
progression-free survival associated with anaplastic lymphoma
kinase (ALK) tyrosine kinase inhibitor therapies for ALK+ non-small
cell lung cancer. Oncologist. 25:867–877. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Xu H, Yang G, Li W, Li J, Hao X, Xing P,
Yang Y and Wang Y: EGFR exon 18 mutations in advanced non-small
cell lung cancer: A real-world study on diverse treatment patterns
and clinical outcomes. Front Oncol. 11:7134832021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang T, Wan B, Zhao Y, Li C, Liu H, Lv T,
Zhan P and Song Y: Treatment of uncommon EGFR mutations in
non-small cell lung cancer: new evidence and treatment. Transl Lung
Cancer Res. 8:302–316. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Heigener DF, Schumann C, Sebastian M,
Sadjadian P, Stehle I, Märten A, Lüers A, Griesinger F and
Scheffler M; Afatinib Compassionate Use Consortium (ACUC), :
Afatinib in non-small cell lung cancer harboring uncommon EGFR
mutations pretreated with reversible EGFR inhibitors. Oncologist.
20:1167–1174. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sehgal K, Rangachari D, VanderLaan PA,
Kobayashi SS and Costa DB: Clinical benefit of tyrosine kinase
inhibitors in advanced lung cancer with EGFR-G719A and other
uncommon EGFR mutations. Oncologist. 26:281–287. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Russo A, Franchina T, Ricciardi G,
Battaglia A, Picciotto M and Adamo V: Heterogeneous responses to
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
(TKIs) in patients with uncommon EGFR mutations: New Insights and
future perspectives in this complex clinical scenario. Int J Mol
Sci. 20:14312019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bai H, Wang Z, Chen K, Zhao J, Lee JJ,
Wang S, Zhou Q, Zhuo M, Mao L, An T, et al: Influence of
chemotherapy on EGFR mutation status among patients with
non-small-cell lung cancer. J Clin Oncol. 30:3077–3083. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Honda Y, Takigawa N, Fushimi S, Ochi N,
Kubo T, Ozaki S, Tanimoto M and Kiura K: Disappearance of an
activated EGFR mutation after treatment with EGFR tyrosine kinase
inhibitors. Lung Cancer. 78:121–124. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Iwama E, Sakai K, Azuma K, Harada T,
Harada D, Nosaki K, Hotta K, Ohyanagi F, Kurata T, Fukuhara T, et
al: Monitoring of somatic mutations in circulating cell-free DNA by
digital PCR and next-generation sequencing during afatinib
treatment in patients with lung adenocarcinoma positive for EGFR
activating mutations. Ann Oncol. 28:136–141. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nagasaka M, Uddin MH, Al-Hallak MN, Rahman
S, Balasubramanian S, Sukari A and Azmi AS: Liquid biopsy for
therapy monitoring in early-stage non-small cell lung cancer. Mol
Cancer. 20:822021. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Qvick A, Stenmark B, Carlsson J, Isaksson
J, Karlsson C and Helenius G: Liquid biopsy as an option for
predictive testing and prognosis in patients with lung cancer. Mol
Med. 27:682021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rolfo C, Mack PC, Scagliotti GV, Baas P,
Barlesi F, Bivona TG, Herbst RS, Mok TS, Peled N, Pirker R, et al:
Liquid biopsy for advanced non-small cell lung cancer (NSCLC): A
statement paper from the IASLC. J Thorac Oncol. 13:1248–1268. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ansari J, Yun JW, Kompelli AR, Moufarrej
YE, Alexander JS, Herrera GA and Shackelford RE: The liquid biopsy
in lung cancer. Genes Cancer. 7:355–367. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gainor JF, Varghese AM, Ou SH, Kabraji S,
Awad MM, Katayama R, Pawlak A, Mino-Kenudson M, Yeap BY, Riely GJ,
et al: ALK rearrangements are mutually exclusive with mutations in
EGFR or KRAS: An analysis of 1,683 patients with non-small cell
lung cancer. Clin Cancer Res. 19:4273–4281. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shaw AT, Yeap BY, Mino-Kenudson M,
Digumarthy SR, Costa DB, Heist RS, Solomon B, Stubbs H, Admane S,
McDermott U, et al: Clinical features and outcome of patients with
non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol.
27:4247–4253. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Horn L and Pao W: EML4-ALK: Honing in on a
new target in non-small-cell lung cancer. J Clin Oncol.
27:4232–4235. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xu L, Lei J, Wang QZ, Li J and Wu L:
Clinical characteristics of patients with non-small cell lung
cancers harboring anaplastic lymphoma kinase rearrangements and
primary lung adenocarcinoma harboring epidermal growth factor
receptor mutations. Genet Mol Res. 14:12973–12983. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pao W, Wang TY, Riely GJ, Miller VA, Pan
Q, Ladanyi M, Zakowski MF, Heelan RT, Kris MG and Varmus HE: KRAS
mutations and primary resistance of lung adenocarcinomas to
gefitinib or erlotinib. PLoS Med. 2:e172005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Thomas D, Maloney ME and Raval G:
Concomitant EGFR mutations and ALK rearrangements in lung
adenocarcinoma treated with osimertinib. Cureus.
15:e481222023.PubMed/NCBI
|
|
28
|
Hu H, Tan S, Xie M, Guo P, Yu Q, Xiao J,
Zhao K, Liao Q and Wang Y: Case report: Concomitant EGFR mutation
and ALK rearrangement in non-small cell lung cancer. Front
Pharmacol. 14:11679592023. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Santelmo C, Ravaioli A, Barzotti E, Papi
M, Poggi B, Drudi F, Mangianti M, Salvi M and Crinò L: Coexistence
of EGFR mutation and ALK translocation in NSCLC: Literature review
and case report of response to gefitinib. Lung Cancer. 81:294–296.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zito Marino F, Ronchi A, Accardo M and
Franco R: Concomitant ALK/KRAS and ALK/EGFR mutations in non small
cell lung cancer: Different profile of response to target
therapies. Transl Cancer Res. 6 (Suppl 3):S457–S460. 2017.
View Article : Google Scholar
|
|
31
|
Zhao N, Zheng SY, Yang JJ, Zhang XC, Xie
Z, Xie B, Su J, Chen ZH, Chen SL, Zhang N, et al: Lung
adenocarcinoma harboring concomitant EGFR mutation and EML4-ALK
fusion that benefits from three kinds of tyrosine kinase
inhibitors: A case report and literature review. Clin Lung Cancer.
16:e5–e9. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lo Russo G, Imbimbo M, Corrao G, Proto C,
Signorelli D, Vitali M, Ganzinelli M, Botta L, Zilembo N, de Braud
F and Garassino MC: Concomitant EML4-ALK rearrangement and EGFR
mutation in non-small cell lung cancer patients: A literature
review of 100 cases. Oncotarget. 8:59889–59900. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zito Marino F, Bianco R, Accardo M, Ronchi
A, Cozzolino I, Morgillo F, Rossi G and Franco R: Molecular
heterogeneity in lung cancer: From mechanisms of origin to clinical
implications. Int J Med Sci. 16:981–989. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chen ZY, Zhong WZ, Zhang XC, Su J, Yang
XN, Chen ZH, Yang JJ, Zhou Q, Yan HH, An SJ, et al: EGFR mutation
heterogeneity and the mixed response to EGFR tyrosine kinase
inhibitors of lung adenocarcinomas. Oncologist. 17:978–985. 2012.
View Article : Google Scholar : PubMed/NCBI
|
